Bonus Material-29_Lung Cancer Part I

Pdf Summary

This comprehensive Lung Cancer Board Review by Dr. Gerard A. Silvestri covers key aspects of lung cancer including epidemiology, screening, diagnosis, staging, and management of solitary pulmonary nodules (SPNs).<br /><br />Epidemiology highlights the US burden with approximately 226,650 new cases and 124,730 deaths projected in 2025. Tobacco smoking causes 80-90% of cases with dose-response relationship, along with other exposures like asbestos and radon. Average diagnosis age is 70 and COPD is a significant risk factor.<br /><br />Histology breakdown: Adenocarcinoma is the most common, especially in non-smokers and females (formerly including bronchioloalveolar carcinoma subtype), followed by squamous cell carcinoma (mostly central, smokers) and small cell lung cancer (SCLC), which is usually metastatic at diagnosis and commonly associated with paraneoplastic syndromes.<br /><br />Screening studies (NLST and NELSON trials) demonstrate lung cancer mortality reductions with low-dose CT, and recommendations now support screening at 50-80 years old with ≥20 pack-years history. Screening identifies many abnormalities, requiring careful nodule evaluation.<br /><br />SPNs require risk stratification using models considering patient age, smoking history, prior malignancy, and nodule size, location, and edge characteristics. Management depends on low (<5%), intermediate, or high (>60%) malignancy risk, ranging from serial CT to biopsy and surgery. PET scanning aids staging but has limitations, especially in infectious areas.<br /><br />Diagnosis includes biopsy techniques (CT-guided fine-needle aspiration, bronchoscopy) and evaluation of metastatic sites. Pleural fluid cytology aids staging but is limited.<br /><br />Lung cancer staging follows the 8th/9th edition TNM classification for tumor size (T), lymph nodes (N), and metastasis (M). SCLC staging distinguishes limited (confined to one hemithorax) versus extensive stage.<br /><br />Assessing surgical candidacy involves physiologic testing of lung function (FEV1, DLCO), predicted postoperative function, and exercise capacity (stair climb, 6-minute walk, cardiopulmonary exercise testing). Risk of perioperative mortality correlates strongly with poor predicted lung function.<br /><br />Overall, the review emphasizes multidisciplinary evaluation for accurate diagnosis, staging, functional assessment, and appropriate treatment selection to improve lung cancer outcomes.

Meta Tag

Concept Lung Cancer

Concept Solitary Pulmonary Nodule

Concept Lung Cancer Screening

Concept Low-Dose Computed Tomography

Concept Lung Cancer Staging

Concept TNM Framework

Keywords

lung cancer

epidemiology

low-dose CT screening

solitary pulmonary nodules

adenocarcinoma

squamous cell carcinoma

small cell lung cancer

TNM staging

biopsy

surgical candidacy

Lung Cancer

Solitary Pulmonary Nodule

Lung Cancer Screening

Low-Dose Computed Tomography

Lung Cancer Staging

TNM Framework